{"transactions":[{"id":940457,"issuer":{"id":7814,"kind":"organization","name":"LISATA THERAPEUTICS, INC.","symbol":"LSTA"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-13T21:02:32.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":30456,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 30,456 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 30,456 unvested restricted stock units."}],"balance_after":104925,"source":{"system":"sec-edgar","filing":"0001309653-26-000004","document":"wk-form4_1768338142.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/320017/000130965326000004/wk-form4_1768338142.xml","form_type":"4"}},{"id":1041992,"issuer":{"id":75335,"kind":"organization","name":"DURECT CORP","symbol":"DRRX"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-09-12T20:17:01.000Z","date":"2025-09-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, prior to the expiration of the tender offer, the vesting or payment of each option to purchase shares outstanding under the Issuer's 2000 Stock Plan, as amended (the \"Issuer Stock Plan\") (each, an \"Issuer Option\"), that had a per share exercise price that was less than the Cash Amount was accelerated. With respect to the shares received upon exercise of such accelerated Issuer Options prior to the Effective Time, all such shares were treated identically with all other shares in connection with the tender offer and the Merger."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(Continued from footnote 3) At the Effective Time, each Issuer Option that had a per share exercise price that was equal to or greater than the Cash Amount, and that was unexercised immediately prior to the Effective Time, was canceled in connection with the Merger. Following the cancellation of each such Issuer Option, each former holder of such Issuer Option is eligible to receive a cash retention bonus subject to the achievement of certain net sales milestones, pursuant to a retention plan approved by the compensation committee of the Issuer's Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, prior to the expiration of the tender offer, the vesting or payment of each option to purchase shares outstanding under the Issuer's 2000 Stock Plan, as amended (the \"Issuer Stock Plan\") (each, an \"Issuer Option\"), that had a per share exercise price that was less than the Cash Amount was accelerated. With respect to the shares received upon exercise of such accelerated Issuer Options prior to the Effective Time, all such shares were treated identically with all other shares in connection with the tender offer and the Merger."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from footnote 3) At the Effective Time, each Issuer Option that had a per share exercise price that was equal to or greater than the Cash Amount, and that was unexercised immediately prior to the Effective Time, was canceled in connection with the Merger. Following the cancellation of each such Issuer Option, each former holder of such Issuer Option is eligible to receive a cash retention bonus subject to the achievement of certain net sales milestones, pursuant to a retention plan approved by the compensation committee of the Issuer's Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, prior to the expiration of the tender offer, the vesting or payment of each option to purchase shares outstanding under the Issuer's 2000 Stock Plan, as amended (the \"Issuer Stock Plan\") (each, an \"Issuer Option\"), that had a per share exercise price that was less than the Cash Amount was accelerated. With respect to the shares received upon exercise of such accelerated Issuer Options prior to the Effective Time, all such shares were treated identically with all other shares in connection with the tender offer and the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from footnote 3) At the Effective Time, each Issuer Option that had a per share exercise price that was equal to or greater than the Cash Amount, and that was unexercised immediately prior to the Effective Time, was canceled in connection with the Merger. Following the cancellation of each such Issuer Option, each former holder of such Issuer Option is eligible to receive a cash retention bonus subject to the achievement of certain net sales milestones, pursuant to a retention plan approved by the compensation committee of the Issuer's Board of Directors."}],"balance_after":0,"derivative":{"exercise_price":1.22,"expiration_date":"2034-09-25","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0000950170-25-114645","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1082038/000095017025114645/ownership.xml","form_type":"4"}},{"id":1041991,"issuer":{"id":75335,"kind":"organization","name":"DURECT CORP","symbol":"DRRX"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-09-12T20:17:01.000Z","date":"2025-09-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, prior to the expiration of the tender offer, the vesting or payment of each option to purchase shares outstanding under the Issuer's 2000 Stock Plan, as amended (the \"Issuer Stock Plan\") (each, an \"Issuer Option\"), that had a per share exercise price that was less than the Cash Amount was accelerated. With respect to the shares received upon exercise of such accelerated Issuer Options prior to the Effective Time, all such shares were treated identically with all other shares in connection with the tender offer and the Merger."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(Continued from footnote 3) At the Effective Time, each Issuer Option that had a per share exercise price that was equal to or greater than the Cash Amount, and that was unexercised immediately prior to the Effective Time, was canceled in connection with the Merger. Following the cancellation of each such Issuer Option, each former holder of such Issuer Option is eligible to receive a cash retention bonus subject to the achievement of certain net sales milestones, pursuant to a retention plan approved by the compensation committee of the Issuer's Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, prior to the expiration of the tender offer, the vesting or payment of each option to purchase shares outstanding under the Issuer's 2000 Stock Plan, as amended (the \"Issuer Stock Plan\") (each, an \"Issuer Option\"), that had a per share exercise price that was less than the Cash Amount was accelerated. With respect to the shares received upon exercise of such accelerated Issuer Options prior to the Effective Time, all such shares were treated identically with all other shares in connection with the tender offer and the Merger."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from footnote 3) At the Effective Time, each Issuer Option that had a per share exercise price that was equal to or greater than the Cash Amount, and that was unexercised immediately prior to the Effective Time, was canceled in connection with the Merger. Following the cancellation of each such Issuer Option, each former holder of such Issuer Option is eligible to receive a cash retention bonus subject to the achievement of certain net sales milestones, pursuant to a retention plan approved by the compensation committee of the Issuer's Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, prior to the expiration of the tender offer, the vesting or payment of each option to purchase shares outstanding under the Issuer's 2000 Stock Plan, as amended (the \"Issuer Stock Plan\") (each, an \"Issuer Option\"), that had a per share exercise price that was less than the Cash Amount was accelerated. With respect to the shares received upon exercise of such accelerated Issuer Options prior to the Effective Time, all such shares were treated identically with all other shares in connection with the tender offer and the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from footnote 3) At the Effective Time, each Issuer Option that had a per share exercise price that was equal to or greater than the Cash Amount, and that was unexercised immediately prior to the Effective Time, was canceled in connection with the Merger. Following the cancellation of each such Issuer Option, each former holder of such Issuer Option is eligible to receive a cash retention bonus subject to the achievement of certain net sales milestones, pursuant to a retention plan approved by the compensation committee of the Issuer's Board of Directors."}],"balance_after":0,"derivative":{"exercise_price":5.29,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0000950170-25-114645","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1082038/000095017025114645/ownership.xml","form_type":"4"}},{"id":1041990,"issuer":{"id":75335,"kind":"organization","name":"DURECT CORP","symbol":"DRRX"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-09-12T20:17:01.000Z","date":"2025-09-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, prior to the expiration of the tender offer, the vesting or payment of each option to purchase shares outstanding under the Issuer's 2000 Stock Plan, as amended (the \"Issuer Stock Plan\") (each, an \"Issuer Option\"), that had a per share exercise price that was less than the Cash Amount was accelerated. With respect to the shares received upon exercise of such accelerated Issuer Options prior to the Effective Time, all such shares were treated identically with all other shares in connection with the tender offer and the Merger."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(Continued from footnote 3) At the Effective Time, each Issuer Option that had a per share exercise price that was equal to or greater than the Cash Amount, and that was unexercised immediately prior to the Effective Time, was canceled in connection with the Merger. Following the cancellation of each such Issuer Option, each former holder of such Issuer Option is eligible to receive a cash retention bonus subject to the achievement of certain net sales milestones, pursuant to a retention plan approved by the compensation committee of the Issuer's Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, prior to the expiration of the tender offer, the vesting or payment of each option to purchase shares outstanding under the Issuer's 2000 Stock Plan, as amended (the \"Issuer Stock Plan\") (each, an \"Issuer Option\"), that had a per share exercise price that was less than the Cash Amount was accelerated. With respect to the shares received upon exercise of such accelerated Issuer Options prior to the Effective Time, all such shares were treated identically with all other shares in connection with the tender offer and the Merger."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from footnote 3) At the Effective Time, each Issuer Option that had a per share exercise price that was equal to or greater than the Cash Amount, and that was unexercised immediately prior to the Effective Time, was canceled in connection with the Merger. Following the cancellation of each such Issuer Option, each former holder of such Issuer Option is eligible to receive a cash retention bonus subject to the achievement of certain net sales milestones, pursuant to a retention plan approved by the compensation committee of the Issuer's Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, prior to the expiration of the tender offer, the vesting or payment of each option to purchase shares outstanding under the Issuer's 2000 Stock Plan, as amended (the \"Issuer Stock Plan\") (each, an \"Issuer Option\"), that had a per share exercise price that was less than the Cash Amount was accelerated. With respect to the shares received upon exercise of such accelerated Issuer Options prior to the Effective Time, all such shares were treated identically with all other shares in connection with the tender offer and the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from footnote 3) At the Effective Time, each Issuer Option that had a per share exercise price that was equal to or greater than the Cash Amount, and that was unexercised immediately prior to the Effective Time, was canceled in connection with the Merger. Following the cancellation of each such Issuer Option, each former holder of such Issuer Option is eligible to receive a cash retention bonus subject to the achievement of certain net sales milestones, pursuant to a retention plan approved by the compensation committee of the Issuer's Board of Directors."}],"balance_after":0,"derivative":{"exercise_price":5.46,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0000950170-25-114645","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1082038/000095017025114645/ownership.xml","form_type":"4"}},{"id":1041989,"issuer":{"id":75335,"kind":"organization","name":"DURECT CORP","symbol":"DRRX"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-09-12T20:17:01.000Z","date":"2025-09-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2750,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, prior to the expiration of the tender offer, the vesting or payment of each option to purchase shares outstanding under the Issuer's 2000 Stock Plan, as amended (the \"Issuer Stock Plan\") (each, an \"Issuer Option\"), that had a per share exercise price that was less than the Cash Amount was accelerated. With respect to the shares received upon exercise of such accelerated Issuer Options prior to the Effective Time, all such shares were treated identically with all other shares in connection with the tender offer and the Merger."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(Continued from footnote 3) At the Effective Time, each Issuer Option that had a per share exercise price that was equal to or greater than the Cash Amount, and that was unexercised immediately prior to the Effective Time, was canceled in connection with the Merger. Following the cancellation of each such Issuer Option, each former holder of such Issuer Option is eligible to receive a cash retention bonus subject to the achievement of certain net sales milestones, pursuant to a retention plan approved by the compensation committee of the Issuer's Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, prior to the expiration of the tender offer, the vesting or payment of each option to purchase shares outstanding under the Issuer's 2000 Stock Plan, as amended (the \"Issuer Stock Plan\") (each, an \"Issuer Option\"), that had a per share exercise price that was less than the Cash Amount was accelerated. With respect to the shares received upon exercise of such accelerated Issuer Options prior to the Effective Time, all such shares were treated identically with all other shares in connection with the tender offer and the Merger."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from footnote 3) At the Effective Time, each Issuer Option that had a per share exercise price that was equal to or greater than the Cash Amount, and that was unexercised immediately prior to the Effective Time, was canceled in connection with the Merger. Following the cancellation of each such Issuer Option, each former holder of such Issuer Option is eligible to receive a cash retention bonus subject to the achievement of certain net sales milestones, pursuant to a retention plan approved by the compensation committee of the Issuer's Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, prior to the expiration of the tender offer, the vesting or payment of each option to purchase shares outstanding under the Issuer's 2000 Stock Plan, as amended (the \"Issuer Stock Plan\") (each, an \"Issuer Option\"), that had a per share exercise price that was less than the Cash Amount was accelerated. With respect to the shares received upon exercise of such accelerated Issuer Options prior to the Effective Time, all such shares were treated identically with all other shares in connection with the tender offer and the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from footnote 3) At the Effective Time, each Issuer Option that had a per share exercise price that was equal to or greater than the Cash Amount, and that was unexercised immediately prior to the Effective Time, was canceled in connection with the Merger. Following the cancellation of each such Issuer Option, each former holder of such Issuer Option is eligible to receive a cash retention bonus subject to the achievement of certain net sales milestones, pursuant to a retention plan approved by the compensation committee of the Issuer's Board of Directors."}],"balance_after":0,"derivative":{"exercise_price":16.6,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":2750},"source":{"system":"sec-edgar","filing":"0000950170-25-114645","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1082038/000095017025114645/ownership.xml","form_type":"4"}},{"id":1041988,"issuer":{"id":75335,"kind":"organization","name":"DURECT CORP","symbol":"DRRX"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-09-12T20:17:01.000Z","date":"2025-09-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, prior to the expiration of the tender offer, the vesting or payment of each option to purchase shares outstanding under the Issuer's 2000 Stock Plan, as amended (the \"Issuer Stock Plan\") (each, an \"Issuer Option\"), that had a per share exercise price that was less than the Cash Amount was accelerated. With respect to the shares received upon exercise of such accelerated Issuer Options prior to the Effective Time, all such shares were treated identically with all other shares in connection with the tender offer and the Merger."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(Continued from footnote 3) At the Effective Time, each Issuer Option that had a per share exercise price that was equal to or greater than the Cash Amount, and that was unexercised immediately prior to the Effective Time, was canceled in connection with the Merger. Following the cancellation of each such Issuer Option, each former holder of such Issuer Option is eligible to receive a cash retention bonus subject to the achievement of certain net sales milestones, pursuant to a retention plan approved by the compensation committee of the Issuer's Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, prior to the expiration of the tender offer, the vesting or payment of each option to purchase shares outstanding under the Issuer's 2000 Stock Plan, as amended (the \"Issuer Stock Plan\") (each, an \"Issuer Option\"), that had a per share exercise price that was less than the Cash Amount was accelerated. With respect to the shares received upon exercise of such accelerated Issuer Options prior to the Effective Time, all such shares were treated identically with all other shares in connection with the tender offer and the Merger."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from footnote 3) At the Effective Time, each Issuer Option that had a per share exercise price that was equal to or greater than the Cash Amount, and that was unexercised immediately prior to the Effective Time, was canceled in connection with the Merger. Following the cancellation of each such Issuer Option, each former holder of such Issuer Option is eligible to receive a cash retention bonus subject to the achievement of certain net sales milestones, pursuant to a retention plan approved by the compensation committee of the Issuer's Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, prior to the expiration of the tender offer, the vesting or payment of each option to purchase shares outstanding under the Issuer's 2000 Stock Plan, as amended (the \"Issuer Stock Plan\") (each, an \"Issuer Option\"), that had a per share exercise price that was less than the Cash Amount was accelerated. With respect to the shares received upon exercise of such accelerated Issuer Options prior to the Effective Time, all such shares were treated identically with all other shares in connection with the tender offer and the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from footnote 3) At the Effective Time, each Issuer Option that had a per share exercise price that was equal to or greater than the Cash Amount, and that was unexercised immediately prior to the Effective Time, was canceled in connection with the Merger. Following the cancellation of each such Issuer Option, each former holder of such Issuer Option is eligible to receive a cash retention bonus subject to the achievement of certain net sales milestones, pursuant to a retention plan approved by the compensation committee of the Issuer's Board of Directors."}],"balance_after":0,"derivative":{"exercise_price":21,"expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0000950170-25-114645","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1082038/000095017025114645/ownership.xml","form_type":"4"}},{"id":1041987,"issuer":{"id":75335,"kind":"organization","name":"DURECT CORP","symbol":"DRRX"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-12T20:17:01.000Z","date":"2025-09-11","kind":"other","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of July 28, 2025 (as amended, the \"Merger Agreement\"), by and among the Issuer, Bausch Health Americas, Inc. (\"Parent\"), BHC Lyon Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Purchaser\"), and solely for the purposes of Section 6.10 of the Merger Agreement, Bausch Health Companies Inc. (\"BHC\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) Tendering stockholders received a consideration of $1.75 per share, net to the seller of such shares in cash, without interest thereon and less any applicable withholding taxes (the \"Cash Amount\"), plus one non-tradeable contingent value right per share, representing the contractual right to receive the pro rata portion, in cash, of two milestone payments of up to $350,000,000 in the aggregate, minus any amount actually paid to option holders under a retention plan in respect of the applicable milestone, in each case, without interest thereon and less any applicable withholding taxes, upon achievement of the specified milestones. After completion of the tender offer, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of September 11, 2025 (the \"Effective Time\"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of July 28, 2025 (as amended, the \"Merger Agreement\"), by and among the Issuer, Bausch Health Americas, Inc. (\"Parent\"), BHC Lyon Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Purchaser\"), and solely for the purposes of Section 6.10 of the Merger Agreement, Bausch Health Companies Inc. (\"BHC\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from footnote 1) Tendering stockholders received a consideration of $1.75 per share, net to the seller of such shares in cash, without interest thereon and less any applicable withholding taxes (the \"Cash Amount\"), plus one non-tradeable contingent value right per share, representing the contractual right to receive the pro rata portion, in cash, of two milestone payments of up to $350,000,000 in the aggregate, minus any amount actually paid to option holders under a retention plan in respect of the applicable milestone, in each case, without interest thereon and less any applicable withholding taxes, upon achievement of the specified milestones. After completion of the tender offer, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of September 11, 2025 (the \"Effective Time\"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of July 28, 2025 (as amended, the \"Merger Agreement\"), by and among the Issuer, Bausch Health Americas, Inc. (\"Parent\"), BHC Lyon Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Purchaser\"), and solely for the purposes of Section 6.10 of the Merger Agreement, Bausch Health Companies Inc. (\"BHC\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) Tendering stockholders received a consideration of $1.75 per share, net to the seller of such shares in cash, without interest thereon and less any applicable withholding taxes (the \"Cash Amount\"), plus one non-tradeable contingent value right per share, representing the contractual right to receive the pro rata portion, in cash, of two milestone payments of up to $350,000,000 in the aggregate, minus any amount actually paid to option holders under a retention plan in respect of the applicable milestone, in each case, without interest thereon and less any applicable withholding taxes, upon achievement of the specified milestones. After completion of the tender offer, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of September 11, 2025 (the \"Effective Time\"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-114645","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1082038/000095017025114645/ownership.xml","form_type":"4"}},{"id":1304643,"issuer":{"id":7814,"kind":"organization","name":"LISATA THERAPEUTICS, INC.","symbol":"LSTA"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-13T21:02:38.000Z","date":"2025-01-09","kind":"grant","planned":false,"acquired":true,"shares":15789,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 15,789 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 22,189 unvested restricted stock units."}],"balance_after":74469,"source":{"system":"sec-edgar","filing":"0001309653-25-000002","document":"wk-form4_1736802148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/320017/000130965325000002/wk-form4_1736802148.xml","form_type":"4"}},{"id":1398663,"issuer":{"id":75335,"kind":"organization","name":"DURECT CORP","symbol":"DRRX"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-09-27T16:16:26.000Z","date":"2024-09-25","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the total number of shares subject to this option grant shall vest and become exercisable on the day before the first anniversary of the date of grant, subject to the Reporting Person continuing to provide services to the Company through the vesting date."}],"balance_after":5500,"derivative":{"exercise_price":1.22,"expiration_date":"2034-09-25","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0000950170-24-110013","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1082038/000095017024110013/ownership.xml","form_type":"4"}},{"id":1681151,"issuer":{"id":7814,"kind":"organization","name":"LISATA THERAPEUTICS, INC.","symbol":"LSTA"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-11T21:02:48.000Z","date":"2024-01-09","kind":"grant","planned":false,"acquired":true,"shares":19480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 19,480 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes  32,280 unvested restricted stock units."}],"balance_after":58680,"source":{"system":"sec-edgar","filing":"0001309653-24-000002","document":"wk-form4_1705006959.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/320017/000130965324000002/wk-form4_1705006959.xml","form_type":"4"}},{"id":1703221,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-20T17:04:23.000Z","date":"2023-12-19","kind":"exercise","planned":false,"acquired":false,"shares":3497,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."}],"balance_after":0,"derivative":{"exercise_price":9.85,"exercise_date":"2016-12-31","expiration_date":"2024-01-13","underlying":"Common Shares","underlying_shares":3497},"source":{"system":"sec-edgar","filing":"0000950170-23-071929","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000095017023071929/ownership.xml","form_type":"4"}},{"id":1703220,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-20T17:04:23.000Z","date":"2023-12-19","kind":"exercise","planned":false,"acquired":false,"shares":823,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."}],"balance_after":0,"derivative":{"exercise_price":9.85,"exercise_date":"2016-12-31","expiration_date":"2024-01-13","underlying":"Common Shares","underlying_shares":823},"source":{"system":"sec-edgar","filing":"0000950170-23-071929","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000095017023071929/ownership.xml","form_type":"4"}},{"id":1703219,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-12-20T17:04:23.000Z","date":"2023-12-19","kind":"exercise","planned":false,"acquired":true,"shares":3497,"price":9.85,"value":34445.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares issued as a result of the exercise are subject to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."}],"balance_after":74225,"source":{"system":"sec-edgar","filing":"0000950170-23-071929","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000095017023071929/ownership.xml","form_type":"4"}},{"id":1703218,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-12-20T17:04:23.000Z","date":"2023-12-19","kind":"exercise","planned":false,"acquired":true,"shares":823,"price":9.85,"value":8106.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares issued as a result of the exercise are subject to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."}],"balance_after":70728,"source":{"system":"sec-edgar","filing":"0000950170-23-071929","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000095017023071929/ownership.xml","form_type":"4"}},{"id":1845631,"issuer":{"id":75335,"kind":"organization","name":"DURECT CORP","symbol":"DRRX"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T17:29:12.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the total shares subject to this grant dated June 21, 2023 shall vest on the day before the first year anniversary of the grant date."}],"balance_after":5500,"derivative":{"exercise_price":5.29,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001209191-23-039459","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1082038/000120919123039459/doc4.xml","form_type":"4"}},{"id":1869263,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-02T17:29:41.000Z","date":"2023-06-02","kind":"grant","planned":false,"acquired":true,"shares":18475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting."}],"balance_after":18475,"derivative":{"exercise_price":38.96,"expiration_date":"2033-06-01","underlying":"Common Shares","underlying_shares":18475},"source":{"system":"sec-edgar","filing":"0000950170-23-026195","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000095017023026195/ownership.xml","form_type":"4"}},{"id":2057066,"issuer":{"id":7814,"kind":"organization","name":"LISATA THERAPEUTICS, INC.","symbol":"LSTA"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-11T21:12:19.000Z","date":"2023-01-09","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 20,000 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 39,200 unvested restricted stock units."}],"balance_after":39200,"source":{"system":"sec-edgar","filing":"0001309653-23-000002","document":"wf-form4_167347152479762.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/320017/000130965323000002/wf-form4_167347152479762.xml","form_type":"4"}},{"id":2087716,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-13T16:29:21.000Z","date":"2022-12-12","kind":"exercise","acquired":false,"shares":3086,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.68,"expiration_date":"2022-12-31","underlying":"Common Shares","underlying_shares":3086},"source":{"system":"sec-edgar","filing":"0001209191-22-060939","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000120919122060939/doc4.xml","form_type":"4"}},{"id":2087715,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-12-13T16:29:21.000Z","date":"2022-12-12","kind":"exercise","acquired":true,"shares":3086,"price":2.68,"value":8270.48,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."}],"balance_after":69905,"source":{"system":"sec-edgar","filing":"0001209191-22-060939","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000120919122060939/doc4.xml","form_type":"4"}},{"id":2157951,"issuer":{"id":7814,"kind":"organization","name":"LISATA THERAPEUTICS, INC.","symbol":"LSTA"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-16T20:46:52.000Z","date":"2022-09-15","kind":"grant","acquired":true,"shares":19200,"price":6.25,"value":120000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 19,200 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock units will vest in equal annual installments over a three-year period with the initial vesting on September 15, 2023."}],"balance_after":19200,"source":{"system":"sec-edgar","filing":"0001309653-22-000005","document":"wf-form4_166336119587195.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/320017/000130965322000005/wf-form4_166336119587195.xml","form_type":"4"}},{"id":2219259,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-29T17:23:53.000Z","date":"2022-06-28","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the common shares subject to the option will vest on the earlier of (i) the first anniversary of grant date and (ii) the day immediately preceding the day of the Issuer's next annual general meeting of shareholders."}],"balance_after":18000,"derivative":{"exercise_price":30.11,"expiration_date":"2032-06-27","underlying":"Common Shares","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-22-039824","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000120919122039824/doc4.xml","form_type":"4"}},{"id":2228634,"issuer":{"id":75335,"kind":"organization","name":"DURECT CORP","symbol":"DRRX"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T16:07:37.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the total shares subject to this grant dated June 15, 2022 shall vest on the day before the first year anniversary of the grant date."}],"balance_after":55000,"derivative":{"exercise_price":0.5463,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-22-037820","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1082038/000120919122037820/doc4.xml","form_type":"4"}},{"id":2257128,"issuer":{"id":75335,"kind":"organization","name":"DURECT CORP","symbol":"DRRX"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-25T20:03:03.000Z","date":"2022-05-24","kind":"purchase","acquired":true,"shares":5000,"price":0.39,"value":1950.0,"ownership":{"direct":true},"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001209191-22-031997","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1082038/000120919122031997/doc4.xml","form_type":"4"}},{"id":2257127,"issuer":{"id":75335,"kind":"organization","name":"DURECT CORP","symbol":"DRRX"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-25T20:03:03.000Z","date":"2022-05-24","kind":"purchase","acquired":true,"shares":10000,"price":0.3889,"value":3889.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions. Prices ranged from $0.3884 to $0.39 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":55000,"source":{"system":"sec-edgar","filing":"0001209191-22-031997","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1082038/000120919122031997/doc4.xml","form_type":"4"}},{"id":2257126,"issuer":{"id":75335,"kind":"organization","name":"DURECT CORP","symbol":"DRRX"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-25T20:03:03.000Z","date":"2022-05-24","kind":"purchase","acquired":true,"shares":5000,"price":0.3789,"value":1894.5,"ownership":{"direct":true},"balance_after":45000,"source":{"system":"sec-edgar","filing":"0001209191-22-031997","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1082038/000120919122031997/doc4.xml","form_type":"4"}},{"id":2257125,"issuer":{"id":75335,"kind":"organization","name":"DURECT CORP","symbol":"DRRX"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-25T20:03:03.000Z","date":"2022-05-24","kind":"purchase","acquired":true,"shares":5000,"price":0.3884,"value":1942.0,"ownership":{"direct":true},"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001209191-22-031997","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1082038/000120919122031997/doc4.xml","form_type":"4"}},{"id":2257124,"issuer":{"id":75335,"kind":"organization","name":"DURECT CORP","symbol":"DRRX"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-25T20:03:03.000Z","date":"2022-05-24","kind":"purchase","acquired":true,"shares":5000,"price":0.3925,"value":1962.5,"ownership":{"direct":true},"balance_after":35000,"source":{"system":"sec-edgar","filing":"0001209191-22-031997","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1082038/000120919122031997/doc4.xml","form_type":"4"}},{"id":2266284,"issuer":{"id":75335,"kind":"organization","name":"DURECT CORP","symbol":"DRRX"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-18T20:05:08.000Z","date":"2022-05-17","kind":"purchase","acquired":true,"shares":1800,"price":0.4213,"value":758.34,"ownership":{"direct":true},"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001209191-22-030276","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1082038/000120919122030276/doc4.xml","form_type":"4"}},{"id":2266283,"issuer":{"id":75335,"kind":"organization","name":"DURECT CORP","symbol":"DRRX"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-18T20:05:08.000Z","date":"2022-05-17","kind":"purchase","acquired":true,"shares":8900,"price":0.4212,"value":3748.68,"ownership":{"direct":true},"balance_after":28200,"source":{"system":"sec-edgar","filing":"0001209191-22-030276","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1082038/000120919122030276/doc4.xml","form_type":"4"}},{"id":2266282,"issuer":{"id":75335,"kind":"organization","name":"DURECT CORP","symbol":"DRRX"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-18T20:05:08.000Z","date":"2022-05-17","kind":"purchase","acquired":true,"shares":9300,"price":0.4193,"value":3899.49,"ownership":{"direct":true},"balance_after":19300,"source":{"system":"sec-edgar","filing":"0001209191-22-030276","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1082038/000120919122030276/doc4.xml","form_type":"4"}},{"id":2266281,"issuer":{"id":75335,"kind":"organization","name":"DURECT CORP","symbol":"DRRX"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-18T20:05:08.000Z","date":"2022-05-16","kind":"purchase","acquired":true,"shares":10000,"price":0.3767,"value":3767.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-22-030276","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1082038/000120919122030276/doc4.xml","form_type":"4"}},{"id":2465577,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-17T16:04:50.000Z","date":"2021-12-15","kind":"exercise","acquired":false,"shares":3086,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/3 of the shares subject to the Option vested on January 1, 2013 (the \"2012 Vesting Commencement Date\") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the 2012 Vesting Commencement Date over the following 2 years."}],"balance_after":0,"derivative":{"exercise_price":3.67,"expiration_date":"2021-12-31","underlying":"Common Shares","underlying_shares":3086},"source":{"system":"sec-edgar","filing":"0001209191-21-070231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000120919121070231/doc4.xml","form_type":"4"}},{"id":2465576,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-12-17T16:04:50.000Z","date":"2021-12-15","kind":"exercise","acquired":true,"shares":3086,"price":3.67,"value":11325.62,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."}],"balance_after":66819,"source":{"system":"sec-edgar","filing":"0001209191-21-070231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000120919121070231/doc4.xml","form_type":"4"}},{"id":2666894,"issuer":{"id":75335,"kind":"organization","name":"DURECT CORP","symbol":"DRRX"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-16T16:30:31.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the total shares subject to this grant dated June 15, 2021 shall vest on the day before the first year anniversary of the grant date."}],"balance_after":27500,"derivative":{"exercise_price":1.66,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":27500},"source":{"system":"sec-edgar","filing":"0001209191-21-040918","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1082038/000120919121040918/doc4.xml","form_type":"4"}},{"id":2682702,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-03T21:02:01.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":18.56,"expiration_date":"2031-06-02","underlying":"Common Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-038058","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000120919121038058/doc4.xml","form_type":"4"}},{"id":2922289,"issuer":{"id":75335,"kind":"organization","name":"DURECT CORP","symbol":"DRRX"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-01-05T20:49:08.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest and become exercisable in installments of one-third of the total number of shares granted on each anniversary of the grant date."}],"balance_after":70000,"derivative":{"exercise_price":2.1,"expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-21-001709","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1082038/000120919121001709/doc4.xml","form_type":"4"}},{"id":2944156,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-15T16:39:55.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"shares":3086,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the\nexchange rate on the date of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option fully vested on December 31, 2013. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3."}],"balance_after":0,"derivative":{"exercise_price":3.76,"expiration_date":"2020-12-31","underlying":"Common Shares","underlying_shares":3086},"source":{"system":"sec-edgar","filing":"0001209191-20-063494","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000120919120063494/doc4.xml","form_type":"4"}},{"id":2944155,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-12-15T16:39:55.000Z","date":"2020-12-15","kind":"exercise","acquired":true,"shares":3086,"price":3.76,"value":11603.36,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the\nexchange rate on the date of exercise."}],"balance_after":63733,"source":{"system":"sec-edgar","filing":"0001209191-20-063494","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000120919120063494/doc4.xml","form_type":"4"}},{"id":3126604,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-02T16:56:10.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":13.11,"expiration_date":"2030-05-31","underlying":"Common Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-033593","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000120919120033593/doc4.xml","form_type":"4"}},{"id":3338512,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-17T17:04:36.000Z","date":"2019-12-16","kind":"exercise","acquired":false,"shares":3086,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option fully vested on December 31, 2012. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3."}],"balance_after":0,"derivative":{"exercise_price":3.56,"expiration_date":"2019-12-31","underlying":"Common Shares","underlying_shares":3086},"source":{"system":"sec-edgar","filing":"0001209191-19-060910","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000120919119060910/doc4.xml","form_type":"4"}},{"id":3338511,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-12-17T17:04:36.000Z","date":"2019-12-16","kind":"exercise","acquired":true,"shares":3086,"price":3.56,"value":10986.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."}],"balance_after":60647,"source":{"system":"sec-edgar","filing":"0001209191-19-060910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000120919119060910/doc4.xml","form_type":"4"}},{"id":3411931,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-09-17T16:46:28.000Z","date":"2019-09-16","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":9.44,"expiration_date":"2029-09-15","underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-049864","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000120919119049864/doc4.xml","form_type":"4"}},{"id":3411930,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-09-17T16:46:28.000Z","date":"2019-09-13","kind":"sale","acquired":false,"shares":23,"price":9.3122,"value":214.1806,"ownership":{"direct":true},"balance_after":57561,"source":{"system":"sec-edgar","filing":"0001209191-19-049864","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000120919119049864/doc4.xml","form_type":"4"}},{"id":3737307,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-12-10T21:10:15.000Z","date":"2018-12-06","kind":"exercise","acquired":false,"shares":3086,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option fully vested on December 31, 2011."}],"balance_after":0,"derivative":{"exercise_price":3.07,"expiration_date":"2018-12-31","underlying":"Common Shares","underlying_shares":3086},"source":{"system":"sec-edgar","filing":"0000899243-18-030608","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000089924318030608/doc4.xml","form_type":"4"}},{"id":3737306,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-12-10T21:10:15.000Z","date":"2018-12-06","kind":"exercise","acquired":true,"shares":3086,"price":3.07,"value":9474.02,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of a lock-up agreement executed by the Reporting Person in favor of the underwriters of the Company's public offering in September 2018."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise."}],"balance_after":57584,"source":{"system":"sec-edgar","filing":"0000899243-18-030608","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000089924318030608/doc4.xml","form_type":"4"}},{"id":3884775,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-22T16:39:41.000Z","date":"2018-06-21","kind":"exercise","acquired":false,"shares":10288,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option fully vested on May 31, 2011."}],"balance_after":0,"derivative":{"exercise_price":3.7,"expiration_date":"2018-06-26","underlying":"Common Shares","underlying_shares":10288},"source":{"system":"sec-edgar","filing":"0001171843-18-004795","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000117184318004795/formfour.xml","form_type":"4"}},{"id":3884774,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-06-22T16:39:41.000Z","date":"2018-06-21","kind":"exercise","acquired":true,"shares":10288,"price":3.7,"value":38065.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise."}],"balance_after":54498,"source":{"system":"sec-edgar","filing":"0001171843-18-004795","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000117184318004795/formfour.xml","form_type":"4"}},{"id":3904704,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-05T16:39:39.000Z","date":"2018-06-04","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":6.2,"expiration_date":"2028-06-03","underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001171843-18-004454","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000117184318004454/form4.xml","form_type":"4"}},{"id":4160065,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2017-11-16T16:56:14.000Z","date":"2017-11-15","kind":"purchase","acquired":true,"shares":15000,"price":2.2187,"value":33280.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $2.2095 to $2.231, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":44210,"source":{"system":"sec-edgar","filing":"0001171843-17-007110","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000117184317007110/formfour.xml","form_type":"4"}},{"id":4202297,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2017-09-25T17:00:39.000Z","date":"2017-09-22","kind":"purchase","acquired":true,"shares":8000,"price":2.95,"value":23600.0,"ownership":{"direct":true},"balance_after":29210,"source":{"system":"sec-edgar","filing":"0001171843-17-005707","document":"form4azab.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000117184317005707/form4azab.xml","form_type":"4"}},{"id":4202296,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2017-09-25T17:00:39.000Z","date":"2017-09-21","kind":"purchase","acquired":true,"shares":2000,"price":2.95,"value":5900.0,"ownership":{"direct":true},"balance_after":21210,"source":{"system":"sec-edgar","filing":"0001171843-17-005707","document":"form4azab.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000117184317005707/form4azab.xml","form_type":"4"}},{"id":4228400,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2017-08-21T16:49:03.000Z","date":"2017-08-18","kind":"purchase","acquired":true,"shares":6312,"price":2.8995,"value":18301.644,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $2.6899 to $2.95, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":19210,"source":{"system":"sec-edgar","filing":"0001171843-17-005194","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000117184317005194/formfour.xml","form_type":"4"}},{"id":4228399,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2017-08-21T16:49:03.000Z","date":"2017-08-17","kind":"purchase","acquired":true,"shares":23,"price":2.65,"value":60.95,"ownership":{"direct":true},"balance_after":12898,"source":{"system":"sec-edgar","filing":"0001171843-17-005194","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000117184317005194/formfour.xml","form_type":"4"}},{"id":4295370,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-02T17:04:41.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date."}],"balance_after":3500,"derivative":{"exercise_price":3.85,"expiration_date":"2027-05-31","underlying":"Common Shares","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001171843-17-003447","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000117184317003447/formfour.xml","form_type":"4"}},{"id":4534974,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-02T18:05:32.000Z","date":"2016-12-01","kind":"exercise","acquired":false,"shares":12345,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option fully vested on December 31, 2009."}],"balance_after":0,"derivative":{"exercise_price":3.21,"expiration_date":"2016-12-31","underlying":"Common Shares","underlying_shares":12345},"source":{"system":"sec-edgar","filing":"0001171843-16-013465","document":"f4_azab120216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000117184316013465/f4_azab120216.xml","form_type":"4"}},{"id":4534973,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2016-12-02T18:05:32.000Z","date":"2016-12-01","kind":"tax_withholding","acquired":false,"shares":4408,"price":7.8,"value":34382.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the terms of a Lock-up Agreement executed by the Reporting Person in favor of the underwriters of the Company's Public Offering in September 2016 (the \"Lock-up\"), the Company withheld the number of shares set forth above pursuant to a net settlement permitted under the terms of the Lock-up.  No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of the Lock-up."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the closing price of the Company's common shares in U.S. dollars on November 30, 2016, which was converted to a Canadian dollar amount for purposes of net settlement calculations."}],"balance_after":12875,"source":{"system":"sec-edgar","filing":"0001171843-16-013465","document":"f4_azab120216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000117184316013465/f4_azab120216.xml","form_type":"4"}},{"id":4534972,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":69464,"kind":"person","name":"AZAB MOHAMMAD","position":1,"cik":"0001309653","reported_name":"AZAB MOHAMMAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2016-12-02T18:05:32.000Z","date":"2016-12-01","kind":"exercise","acquired":true,"shares":12345,"price":3.21,"value":39627.45,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise."}],"balance_after":17283,"source":{"system":"sec-edgar","filing":"0001171843-16-013465","document":"f4_azab120216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309653/000117184316013465/f4_azab120216.xml","form_type":"4"}}]}